At a glance
ClinicalIndex Comparison Record- ✓Age ≥18 years at time of signing ICF
- ✓Confirmed HCC diagnosis by histopathology or typical imaging (dynamic CT/MRI per AASLD criteria)
- ✓Intermediate-stage HCC not amenable to curative surgery/transplant/ablation but amenable to TACE
- ✓No massive multinodular pattern preventing adequate TACE
- ✕Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma-HCC (if biopsy-proven)
- ✕Prior treatment with atezolizumab or bevacizumab
- ✕Prior PD-1, PD-L1, or CTLA-4 inhibitors or any cancer immunotherapy for HCC
- ✕Clinically meaningful ascites requiring non-pharmacologic intervention (paracentesis)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The ABC-HCC Trial: A Phase IIIb, Randomized, Multicenter, Open-label Trial of Atezolizumab Plus Bevacizumab Versus Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma
In Brief
A Phase 3 clinical trial evaluating Atezolizumab, Bevacizumab, and 1 other intervention for Hepatocellular Carcinoma. Currently recruiting, targeting 434 participants across 72 sites in 6 countries.
Signals
Detailed Summary
The ABC-HCC trial is a Phase IIIb, randomised, multicenter, open-label study designed to evaluate the safety and efficacy of atezolizumab plus bevacizumab versus TACE in patients with intermediate-stage HCC. Approximately 434 patients in two arms of treatment will be enrolled.
Study Details
Timeline
Interventions
1200 mg atezolizumab intravenously Q3W (max 32 cycles, up to 24 months)
15 mg/kg intravenously Q3W (max 32 cycles, up to 24 months)
Locoregional therapy will be performed as a standard-of-care procedure